Acetyl-L-carnitine deficiency in patients with major depressive disorder

Proceedings of the National Academy of Sciences of the United States of America

Volumn 115, Issue 34, 2018, Pages 8627-8632

  Nasca, Carla ^a   Bigio, Benedetta ^a   Lee, Francis S ^b   Young, Sarah P ^c,d   Kautz, Marin M ^e   Albright, Ashly ^b   Beasley, James ^d   Millington, David S ^c,d   Mathé, Aleksander A ^f   Kocsis, James H ^b   Murrough, James W ^e   McEwen, Bruce S ^a   Rasgon, Natalie ^a,g  

^a ROCKEFELLER UNIVERSITY   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d DUKE UNIVERSITY HEALTH SYSTEM   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f KAROLINSKA INSTITUTE   (Sweden)

^g STANFORD UNIVERSITY   (United States)

Author keywords

Childhood trauma; Epigenetic; Glutamate; MGlu2; Treatment resistant depression

Indexed keywords

LEVACECARNINE; ACETYLCARNITINE; CARNITINE;

AGE; AMINO ACID DEFICIENCY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHILDHOOD INJURY; CONTROLLED STUDY; DISEASE SEVERITY; ENDOPHENOTYPE; EXPLORATORY RESEARCH; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MEDICAL HISTORY; NEGLECT; NONHUMAN; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROTEIN FUNCTION; SEX; TREATMENT RESISTANT DEPRESSION; ADULT; AGED; BLOOD; CLINICAL TRIAL; DEFICIENCY; MIDDLE AGED; SEX FACTOR;

ACETYLCARNITINE; ADULT; AGE FACTORS; AGED; CARNITINE; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; MIDDLE AGED; SEX FACTORS;

EID: 85051829348     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1801609115     Document Type: Article

References (44)

1. Kessler RC, Bromet EJ (2013) The epidemiology of depression across cultures. Annu Rev Public Health 34:119–138.
2. Friedrich MJ (2017) Depression is the leading cause of disability around the world. JAMA 317:1517.
3. Rasgon NL, McEwen BS (2016) Insulin resistance: A missing link no more. Mol Psychiatry 21:1648–1652.
4. McIntyre RS, et al. (2009) Metabolic syndrome and major depressive disorder: Co-occurrence and pathophysiologic overlap. Curr Diab Rep 9:51–59.
5. Nemeroff CB (2016) Paradise lost: The neurobiological and clinical consequences of child abuse and neglect. Neuron 89:892–909.
6. Schmidt HD, Shelton RC, Duman RS (2011) Functional biomarkers of depression: Diagnosis, treatment, and pathophysiology. Neuropsychopharmacology 36:2375–2394.
7. Gururajan A, Clarke G, Dinan TG, Cryan JF (2016) Molecular biomarkers of depression. Neurosci Biobehav Rev 64:101–133.
8. Nestler EJ (2014) Epigenetic mechanisms of depression. JAMA Psychiatry 71:454–456.
9. Tsankova NM, et al. (2006) Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat Neurosci 9:519–525.
10. Nasca C, et al. (2013) L-acetylcarnitine causes rapid antidepressant effects through the epigenetic induction of mGlu2 receptors. Proc Natl Acad Sci USA 110:4804–4809.
11. Russo SJ, Charney DS (2013) Next generation antidepressants. Proc Natl Acad Sci USA 110:4441–4442.
12. Flight MH (2013) Antidepressant epigenetic action. Nat Rev Neurosci 14:226.
13. Wang SM, et al. (2014) A review of current evidence for acetyl-L-carnitine in the treatment of depression. J Psychiatr Res 53:30–37.
14. Wang W, et al. (2015) Rapid-acting antidepressant-like effects of acetyl-L-carnitine mediated by PI3K/AKT/BDNF/VGF signaling pathway in mice. Neuroscience 285: 281–291.
15. Madiraju P, Pande SV, Prentki M, Madiraju SR (2009) Mitochondrial acetylcarnitine provides acetyl groups for nuclear histone acetylation. Epigenetics 4:399–403.
16. Lau T, Bigio B, Zelli D, McEwen BS, Nasca C (2017) Stress-induced structural plasticity of medial amygdala stellate neurons and rapid prevention by a candidate antidepressant. Mol Psychiatry 22:227–234.
17. Pettegrew JW, Levine J, McClure RJ (2000) Acetyl-L-carnitine physical–chemical, metabolic, and therapeutic properties: Relevance for its mode of action in Alzheimer’s disease and geriatric depression. Mol Psychiatry 5:616–632.
18. Cuccurazzu B, et al. (2013) Upregulation of mGlu2 receptors via NF-κB p65 acetylation is involved in the proneurogenic and antidepressant effects of acetyl-L-carnitine. Neuropsychopharmacology 38:2220–2230.
19. Bigio B, et al. (2016) Epigenetics and energetics in ventral hippocampus mediate rapid antidepressant action: Implications for treatment resistance. Proc Natl Acad Sci USA 113:7906–7911.
20. Nasca C, et al. (2017) Role of the astroglial glutamate exchanger xCT in ventral hippocampus in resilience to stress. Neuron 96:402–413.e5.
21. McEwen BS, et al. (2015) Mechanisms of stress in the brain. Nat Neurosci 18: 1353–1363.
22. Fritz IB, McEwen B (1959) Effects of carnitine on fatty-acid oxidation by muscle. Science 129:334–335.
23. Scafidi S, et al. (2010) Metabolism of acetyl-L-carnitine for energy and neurotransmitter synthesis in the immature rat brain. J Neurochem 114:820–831.
24. Mitani H, et al. (2006) Correlation between plasma levels of glutamate, alanine and serine with severity of depression. Prog Neuropsychopharmacol Biol Psychiatry 30:1155–1158.
25. Lin KW, Wroolie TE, Robakis T, Rasgon NL (2015) Adjuvant pioglitazone for un-remitted depression: Clinical correlates of treatment response. Psychiatry Res 230: 846–852.
26. Rasgon NL, et al. (2010) Rosiglitazone add-on in treatment of depressed patients with insulin resistance: A pilot study. Sci World J 10:321–328.
27. Duman RS, Li N (2012) A neurotrophic hypothesis of depression: Role of synapto-genesis in the actions of NMDA receptor antagonists. Philos Trans R Soc Lond B Biol Sci 367:2475–2484.
28. Zarate CA, Jr, Machado-Vieira R (2017) Ketamine: Translating mechanistic discoveries into the next generation of glutamate modulators for mood disorders. Mol Psychiatry 22:324–327.
29. Monteggia LM, Zarate C, Jr (2015) Antidepressant actions of ketamine: From molecular mechanisms to clinical practice. Curr Opin Neurobiol 30:139–143.
30. Raison CL, Miller AH (2011) Is depression an inflammatory disorder? Curr Psychiatry Rep 13:467–475.
31. Miller AH, Raison CL (2016) The role of inflammation in depression: From evolutionary imperative to modern treatment target. Nat Rev Immunol 16:22–34.
32. Lu Y, et al. (2016) Acetylcarnitine is a candidate diagnostic and prognostic biomarker of hepatocellular carcinoma. Cancer Res 76:2912–2920.
33. (2018) Inventory of Depressive Symptomatology (IDS) and Quick Inventory of Depressive Symptomatology (QIDS). Available at www.ids-qids.org/interpretation.html. Accessed June 15, 2018.
34. Bernstein DP, et al. (1994) Initial reliability and validity of a new retrospective measure of child abuse and neglect. Am J Psychiatry 151:1132–1136.
35. van Vlies N, et al. (2005) Characterization of carnitine and fatty acid metabolism in the long-chain acyl-CoA dehydrogenase-deficient mouse. Biochem J 387:185–193.
36. Garcia M, et al. (2016) Sex differences in the effect of childhood trauma on the clinical expression of early psychosis. Compr Psychiatry 68:86–96.
37. Williams LM, Debattista C, Duchemin AM, Schatzberg AF, Nemeroff CB (2016) Childhood trauma predicts antidepressant response in adults with major depression: Data from the randomized international study to predict optimized treatment for depression. Transl Psychiatry 6:e799.
38. Kapczinski F, et al. (2008) Allostatic load in bipolar disorder: Implications for pathophysiology and treatment. Neurosci Biobehav Rev 32:675–692.
39. Meister R, et al. (2016) Comparative safety of pharmacologic treatments for persistent depressive disorder: A systematic review and network meta-analysis. PLoS One 11: e0153380.
40. Veronese N, et al. (2018) Acetyl-L-carnitine supplementation and the treatment of depressive symptoms: A systematic review and meta-analysis. Psychosom Med 80: 154–159.
41. Souery D, Papakostas GI, Trivedi MH (2006) Treatment-resistant depression. J Clin Psychiatry 67:16–22.
42. Russell JM, et al. (2004) The cost consequences of treatment-resistant depression. J Clin Psychiatry 65:341–347.
43. Bernstein DP, et al. (2003) Development and validation of a brief screening version of the Childhood Trauma Questionnaire. Child Abuse Negl 27:169–190.
44. Kiraly DD, et al. (2017) Altered peripheral immune profiles in treatment-resistant depression: Response to ketamine and prediction of treatment outcome. Transl Psychiatry 7:e1065.